• Vaccine Name: MVA- Malaria-CSP
• Target Pathogen: malaria
• Type: Recombinant vector vaccine
• Status: Licensed
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001107
• Preparation: Recombinant viral vaccines fowlpox strain FP9 and modified virus Ankara (MVA), a protein vaccine (CV-1866), or a combination of the two; all vaccines express parts of the same preerythrocytic malaria antigen, the Plasmodium berghei circumsporozoite protein (CSP (Hutchings et al., 2007).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Mice were immunized with the recombinant viral vaccines fowlpox strain FP9 and modified virus Ankara (MVA), a protein vaccine (CV-1866), or a combination of the two; all vaccines express parts of the same preerythrocytic malaria antigen, the Plasmodium berghei circumsporozoite protein (CSP) (Hutchings et al., 2007).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were then challenged with P. berghei sporozoites to determine the protective efficacies of different vaccine regimens (Hutchings et al., 2007).
• Efficacy: Two immunizations with the protein vaccine CV-1866, based on the hepatitis B core antigen particle, induced strong humoral immunity to the repeat region of CSP that was weakly protective against sporozoite challenge. Prime-boost with the viral vector vaccines, FP9 followed by MVA, induced strong T-cell immunity to the CD8+ epitope Pb9 and partially protected animals from challenge. Physically mixing CV-1866 with FP9 or MVA and then immunizing with the resultant combinations in a prime-boost regimen induced both cellular and humoral immunity and afforded substantially higher levels of protection (combination, 90%) than either vaccine alone (Hutchings et al., 2007).